Shandong Weigao Group Medical Polymer Résultats passés
Passé contrôle des critères 2/6
Shandong Weigao Group Medical Polymer a connu une croissance annuelle moyenne de ses bénéfices de 4.2%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en hausse à 14.7% par an. Les revenus ont augmenté de en hausse à un taux moyen de 6.4% par an. Le rendement des capitaux propres de Shandong Weigao Group Medical Polymer est 8% et ses marges nettes sont de 14.7%.
Informations clés
4.2%
Taux de croissance des bénéfices
4.0%
Taux de croissance du BPA
| Medical Equipment Croissance de l'industrie | 13.7% |
| Taux de croissance des recettes | 6.4% |
| Rendement des fonds propres | 8.0% |
| Marge nette | 14.7% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital
Nov 04
Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report
Sep 24Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target
Aug 30Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk
Jun 25Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return
Jun 23Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year
May 31We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope
May 22Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Apr 23Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results
Mar 28Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon
Jan 09Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 22Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?
Nov 10Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Oct 05Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing
Aug 01Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?
Jul 19Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Jun 22Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?
Jun 09The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Apr 27Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Mar 17A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Feb 27Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes
Jan 18Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Dec 12Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate
Nov 29Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today
Nov 14Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year
Oct 03The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Sep 21Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt
Sep 05Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price
Aug 23Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors
Aug 08There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital
Jun 22Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year
Jun 08An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued
May 16Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?
May 03Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher
Mar 17Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?
Jan 28Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?
Jan 13Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 17Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly
Dec 05An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued
Oct 18Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?
Oct 06Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Shandong Weigao Group Medical Polymer gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 12,967 | 1,912 | 3,778 | 600 |
| 31 Mar 24 | 13,098 | 1,957 | 3,807 | 596 |
| 31 Dec 23 | 13,229 | 2,002 | 3,837 | 593 |
| 30 Sep 23 | 13,398 | 2,221 | 3,793 | 597 |
| 30 Jun 23 | 13,566 | 2,440 | 3,748 | 602 |
| 31 Mar 23 | 13,657 | 2,602 | 3,721 | 579 |
| 31 Dec 22 | 13,747 | 2,764 | 3,694 | 556 |
| 30 Sep 22 | 13,903 | 2,676 | 3,725 | 551 |
| 30 Jun 22 | 14,058 | 2,589 | 3,755 | 546 |
| 31 Mar 22 | 13,633 | 2,432 | 3,793 | 525 |
| 31 Dec 21 | 13,209 | 2,276 | 3,830 | 503 |
| 30 Sep 21 | 12,923 | 2,288 | 3,865 | 493 |
| 30 Jun 21 | 12,636 | 2,300 | 3,900 | 484 |
| 31 Mar 21 | 12,129 | 2,194 | 3,775 | 454 |
| 31 Dec 20 | 11,622 | 2,087 | 3,651 | 424 |
| 30 Sep 20 | 11,139 | 1,998 | 3,636 | 403 |
| 30 Jun 20 | 10,656 | 1,909 | 3,622 | 382 |
| 31 Mar 20 | 10,520 | 1,879 | 3,699 | 394 |
| 31 Dec 19 | 10,384 | 1,850 | 3,776 | 406 |
| 30 Sep 19 | 9,993 | 1,805 | 3,696 | 374 |
| 30 Jun 19 | 9,602 | 1,760 | 3,615 | 341 |
| 31 Mar 19 | 9,205 | 1,616 | 3,500 | 326 |
| 31 Dec 18 | 8,809 | 1,473 | 3,385 | 311 |
| 30 Jun 18 | 7,465 | 1,255 | 2,842 | 280 |
| 31 Mar 18 | 6,879 | 1,255 | 2,593 | 277 |
| 31 Dec 17 | 6,293 | 1,255 | 2,344 | 274 |
| 30 Jun 17 | 5,402 | 1,297 | 1,918 | 258 |
| 31 Mar 17 | 5,511 | 1,165 | 2,062 | 262 |
| 31 Dec 16 | 5,620 | 1,033 | 2,206 | 266 |
| 30 Sep 16 | 6,484 | 1,010 | 2,469 | 302 |
| 30 Jun 16 | 6,237 | 914 | 2,367 | 302 |
| 31 Mar 16 | 6,078 | 1,013 | 2,153 | 297 |
| 31 Dec 15 | 5,919 | 1,113 | 1,938 | 293 |
| 30 Sep 15 | 5,878 | 1,237 | 1,920 | 290 |
| 30 Jun 15 | 5,610 | 1,196 | 1,839 | 262 |
| 31 Mar 15 | 5,548 | 1,161 | 1,828 | 252 |
| 31 Dec 14 | 5,278 | 1,085 | 1,742 | 238 |
| 30 Sep 14 | 5,011 | 307 | 1,646 | 222 |
| 30 Jun 14 | 4,996 | 431 | 1,583 | 222 |
| 31 Mar 14 | 4,769 | 376 | 1,521 | 215 |
| 31 Dec 13 | 4,613 | 388 | 1,453 | 209 |
Des revenus de qualité: 1066 a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de 1066 sont inférieures à celles de l'année dernière 1066. (14.7%) sont inférieures à celles de l'année dernière (18%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de 1066 ont augmenté de 4.2% par an au cours des 5 dernières années.
Accélération de la croissance: 1066 a connu une croissance négative de ses bénéfices au cours de l'année écoulée, elle ne peut donc pas être comparée à sa moyenne sur 5 ans.
Bénéfices par rapport au secteur d'activité: 1066 a enregistré une croissance négative de ses bénéfices ( -21.6% ) au cours de l'année écoulée, ce qui rend difficile la comparaison avec la moyenne du secteur Medical Equipment ( -4.3% ).
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de 1066 ( 8% ) est considéré comme faible.